Mumbai: Sanofi India Ltd today announced the launch of AllStar, its first indigenously manufactured reusable insulin pen.
"We have launched AllStar, an indigenously manufactured reusable insulin pen at an affordable price of Rs 650 per unit. It is developed for Indian patients by Sanofi`s medical device development team in Frankfurt," Sanofi India`s managing director Shailesh Ayyangar told reporters here.
AllStar is custom-made for patients in India and it will help improve both insulin initiation and compliance and bring ease and reassurance to the lives of Indian patents, giving them the convenience of international standards at an affordable price, he said.
Incidentally, India has the second highest number of diabetics in the world estimated at 62 million.
The company has also received enquiries from other emerging markets in Asia and Africa, Ayyangar said.
Dr Shashank Joshi, President, Indian Academy of Diabetes, said, "In India, on an average, doctors prescribe insulin therapy to about one-third of their diabetes patients. Close to 75 percent patients are on vials with syringes and 25 percent on insulin pens.
Insulin pens definitely offer greater advantage than vials and syringes in terms of ease of usage thereby increasing patient initiation and compliance to therapy, Joshi said.